Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + docetaxel + tamoxifen + cyclophosphamide
- Development stage
- Phase 3
- Lead developer
- Farmitalia
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy and hormonal therapy regimen used in the treatment of breast cancer. This regimen typically consists of doxorubicin (an anthracycline), docetaxel (a taxane), cyclophosphamide (an alkylating agent), and tamoxifen (a selective estrogen receptor modulator). The drugs may be administered sequentially or in specific combinations, with tamoxifen often given after completion of chemotherapy for hormone receptor-positive disease. This combination has shown efficacy in both early-stage and metastatic breast cancer settings.
02
Targets
DNAESR1 (ERα)ESR2 (ERβ)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin + docetaxel + tamoxifen + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + docetaxel + tamoxifen + cyclophosphamide.